

Press Release

Malaysian Company Provides Biomanufacturing Services To Indian Biotech Company

Inno Biologics enters into 5 year biopharmaceutical manufacturing business agreement

Boston, 7 May 2007 – Inno Biologics announced its first manufacturing agreement with Indian-based company, Avesta Biotherapeutics & Research Pvt. Ltd. at an exchange of document ceremony held at the BIO International Convention here today. The event was witnessed by the Deputy Prime Minister of Malaysia, YAB Dato' Sri Mohd. Najib Tun Abdul Razak and the Minister of Science, Technology and Innovation, YB Dato' Sri Dr. Jamaludin bin Datuk Mohd. Jarjis.

Avesta Biotherapeutics & Research Pvt. Ltd. (ABRPL) is a fast expanding biopharmaceutical company in Bangalore, India, with its core business focusing on development of biopharmaceuticals in the area of autoimmune disorders and cancers. Whilst Inno Biologics is a medium sized Malaysian CMO which offers the similar services in small scale GMP biomanufacturing which mainly focuses on Phase I and Phase II clinical trial material productions. Located in Putra Nilai, Negeri Sembilan in Malaysia, Inno Biologics' 1,000 litre GMP facility has been completed in July 2006. The facility, built to conform to US Food and Drug Administration (FDA) and European Medical Agency (EMA) standards, was constructed based on modular concept by Pharmaplan International, Germany.

Significant milestone achieved

The business partnership between Inno Biologics and ABRPL is a five-year contract agreement of development and biomanufacturing of several biopharmaceuticals. YBhg Dato' Dr. Mohd. Nazlee Kamal, the CEO of Inno Biologics, signified this as a great milestone of the company. "I believe that this business agreement will path the way for more opportunities for Inno Biologics to thrive on the global platform. We aspire to establish a solid footprint in the global marketplace, and this international recognition boosts a strong motivation for us to exceed our customer's expectations."

When asked what brings the two companies to establish a business partnership, Dr Villoo Morawala Patell, the founder of ABRPL said, "The astute management of Inno Biologics and its unique offerings are the key influencing factors that made us choose Inno Biologics as the partner of choice. Dr. Villoo pointed out that one of the unique offerings of Inno Biologics is its remarkable effort to offer an array of platform technologies to complement its existing range of services. "Furthermore, the capacity of its facility is an ideal match to our requirements," she added. She also believes that Malaysia is a strategic place for such endeavours, thanks to its excellent logistics and strong biotech industry growth. The strong government support and the established clinical trial network in the

country are also appealing to ABRPL as part of its ongoing biopharmaceutical product development strategies.

Inno Biologics also has a strategic collaboration with CIMAB S.A., the commercial arm of Centre of Molecular Immunology (CIM), Cuba, involving technology licensing for the Humanization of Antibody. This is part of Inno Biologics' growth strategies to continue enhancing its services to its clients.

YAB Dato' Sri Mohd. Najib Tun Abdul Razak, regarded the achievement of Inno Biologics as an excellent progress of Malaysia's market entry in the global biotechnology market. "Inno Biologics serves as a role model and it has brought encouragement to the domestic biotech community. The Government has provided full support for the development of the biotech industry and created a conducive environment which includes financial incentives and Intellectual Property protection. The nation takes pride of the company's achievement and it is hoped that this will be the beginning of the continued success of the company." Dato' Sri added, "Inno Biologics also has been awarded the Bionexus status in Malaysia which allows it to enjoy a 10 – year period of tax exemption. This award is given on an annual basis to biotech companies which fulfil certain criteria. This award reflects the seriousness of the governmental support provided to biotech companies in Malaysia."

About Inno Biologics

Inno Biologics Sdn. Bhd. is the key company of Inno Bio Ventures Sdn. Bhd., a Malaysian Ministry of Finance Incorporated Company with a close affiliation with Ministry of Science, Technology and Innovation of Malaysia.

Inno Biologics' services encompass gene cloning and expression using mammalian cell expression system; bioprocess development and cGMP biopharmaceutical manufacturing.

Inno Biologics provides biopharmaceutical manufacturing services to local and international bio pharmaceutical companies. Its world class cGMP facility is built to conform to US FDA, EMEA and PIC/S regulations.

As a company awarded with BioNexus Status, Inno Biologics enjoys 100% income tax exemption for 10 years commencing from the first year the company derives profit.

About Avesta Biotherapeutics & Research Pvt. Ltd.

Avesta Biotherapeutics & Research Pvt. Ltd. (ABRPL) is a joint venture company between Avesthagen (Avestha Gengraine Technologies Pvt. Ltd.) and Meditab, an affiliate of Cipla.

ABRPL is based in Bangalore, India, and it was established to manufacture a new generation of targeted therapies that are already in development. The synergy

of Avesthagen-Cipla enables a tie-up of Aveshagen's technology development prowess and Cipla's marketing strengths. The drug development partnership is currently focusing on the development of biopharmaceuticals in the area of autoimmune disorders and cancers.

For further information, please contact:

Soheir Khatib
Senior Manager of Corporate Strategy
Inno Biologics Sdn. Bhd.
Phone: +606 799 6661 or +606 799 6662
Fax: +606 799 6660
E-mail: soheir.khatib@innobiologics.com